Orexin A
Orexin receptor agonist
Endogenous hypothalamic neuropeptide that activates the OX1R and OX2R receptors, studied in feeding, wakefulness, arousal and reward research.
Evidence level. Published human clinical data exists, from trials or approved use. About the badges
- Class
- Orexin receptor agonist
- Category
- Neuro, Cognitive & Sleep
- Type
- Single compound
- Development and regulatory status
- Not approved; endogenous neuropeptide used experimentally
What researchers study
Endogenous hypothalamic neuropeptide that activates both orexin receptors, OX1R and OX2R. It was identified as a regulator of feeding and is now studied in wakefulness, arousal and reward circuits.
Research areas
- Sleep-wake regulation and arousal circuits
- Feeding behaviour in rodent models
- Narcolepsy-related orexin-deficiency models
- Reward and motivation circuitry
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- rodent
Orexin-A and -B were identified in 1998 and both stimulated food consumption in rats
- review
A 2024 systematic review of three human narcolepsy type 1 studies reported fewer wake-REM transitions and less total REM time with orexin-A, without increased wake time
Studied alongside
Compounds that appear together in research because their mechanisms complement each other, or as comparators. The reasons given are research reasoning, not recommendations for use.
